Allarity priming itself for a pumpAs with most micro biotech companies, I expect the price to continue to fall to the $1 region and then “flatten out” for a while to keep its head just above the minimum listing requirement. It will then probably remain there until it is seemingly forgotten.
Then, in a move to regain compliance (if it falls below $1) we can expect some financial reorganisation on the stocks behalf and possibly a R/S on the cards if things get dire.
If it remains over the minimum listing price, I expect some group of pumpers to catch on to Allarity and we could see a few weeks of growing buzz on social media platforms, followed by some handy articles and a sudden parabolic move upwards on news as FOMO kicks in to the herd.
Biotechnology
ATOS Weekly Shaping UpWe can see that the weekly chart is showing some exhaustion on the sell pressure. The daily has a bit of a heartbeat today breaking over the 20ema/ma.
Looking to see the weekly SARs flip underneath to support price, and a break over the T Line (EMA8) on the weekly to confirm a trend change.
If there is a solid break, targets (based on current price but will change) would be:
Weekly 20ema - 2.04
Weekly 50ema - 2.53
Weekly 100ema - 3.24
Anything over would just be cream. Unless they finally go phase 3 for endoxifen, but I'm sticking to TA.
$APM Target PTs 7-14 Long term PT 30 and higherAptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer
The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma.
Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in 2022.
Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% - 10% of all childhood tumors, accounting for around 15% of all cancer-related deaths in the pediatric population.
Aptorum received its first US patent regarding SACT-1 repurposed drug for various cancers earlier this week.
The SACT-1 invention provides a composition and method for treating or preventing the growth of cancerous tumors and/or delaying the onset of cancer from tumor-initiating cells.
Price Action: APM shares are up 30.3% at $1.59 during the premarket session on the last check Thursday.
See more from Benzinga
FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors
EXCLUSIVE: Alfi Inks AI Tech Deal For Improved Passenger Experience At BWI Thurgood Marshall Airport
Bayer AG (BAYN.de) bullish scenario:The technical figure Channel Down can be found in the German company Bayer AG (BAYN.de) at daily chart. Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds, and biotechnology products. The company is a component of the Euro Stoxx 50 stock market index. The Channel Down has broken through the resistance line on 12/01/2021, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 49 days towards 54.270 EUR. Your stop loss order according to experts should be placed at 43.905 EUR if you decide to enter this position.
Bayer AG on Monday struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen its cell and gene therapy development efforts.
Unlisted U.S. biotech firm Mammoth will initially receive $40 million from Bayer plus potential milestone payments of more than $1 billion contingent on scientific and commercial achievements.
The initial focus of the collaboration will be liver-based diseases, the companies said in a joint statement on Monday.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
$KPRX Target PT 2 and higherKiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference
Salt Lake City, Utah--(Newsfile Corp. - January 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian Strem, Ph.D., President and Chief Executive Officer, will provide an outlook for the business and its pipeline of treatments for ophthalmic diseases.
The corporate presentation will be available on-demand and accessible from the Company's Investor Relations website starting Monday January 10, 2022 at 7:00 am Eastern Time.
About Kiora
Kiora is a clinical-stage biotechnology company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase ("DHODH") with best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with other DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing. For more information, please visit www.kiorapharma.com.
Forward-Looking Statements
Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2021 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.
AEZS European approval to market MacrillenAEterna has a variety of new products in its pipeline.
Macrilen, for example, is the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency.
AEterna received European approval to market Macrillen.
Dr. Christian Strasburger: "Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition.”
I think AEZS is a sleeping giant.
My price target is $1.25.
BMY to break out in the next several yearsBMY is presently in a wedge. Though a breakdown is certainly possible over the next decade, what are reasonable breakout levels to watch? This chart with Fib levels induced by the move from all-time lows to all-time highs gives some clues.
Approximately $75 is first up, then approximately $120.
Humanigen is ready to reverseHumanigen's stock has two lower trend resistance lines with price targets of $3 and $2, respectively.
The first resistance line has just hit after a month of major events.
Catalyst 1: Marc Bistricer of Murchison and Nomis Bay bought back in after major selling over the past year.
Catalyst 2: 7 corporate insiders including the CEO (Cameron Durrant) and Chief Scientific Officer (Dale Chappell) announced taking sizable call options at strikes between $0 and $2.85 in lieu of salary.
Catalyst 3: Bad news is out and priced in (or largely priced in). The FDA and MHRA have both informed HGEN that its applications to license lenzilumab, the company's proprietary anti-cytokine-storm therapeutic, are delayed pending further data on efficacy, safety, and manufacturing.
Catalyst 4: In December the findings from the 2020-2021 LIVE-AIR trial were published in The Lancet, one of the top 5 medical journals in the world.
Catalyst 5: the confirmatory ACTIV-5 BET trial sponsored by the NIH is now fully enrolled. The interim data readout is expected at the very earliest in late February, at the latest in early March. The FDA and MHRA will ultimately decide whether to give emergency authorization for lenzilumab as a COVID therapeutic based on the ACTIV-5 results.
Record financials warrant a re-ratingQ3 2021 results warrant a re-rating of this $30M mkt cap biotech play:
- Revenue was $25.3 million in the third quarter of 2021, up 575%, compared to $3.7 million over the prior three-month period ending June 30, 2021.
- Gross profit was $10.5 million in the third quarter of 2021, up 1,288%, compared to $753,535 over the prior three-month period ending June 30, 2021.
- Net income was $6.8 million in the third quarter of 2021, compared to a net loss of $8.7 million over the prior three-month period ending June 30, 2021.
$BFRI entry PT 6 Target PT 11-20 and higherNote: ER 11/30 Tues
Roth Capital analyst Jonathan Aschoff initiated coverage of BFRI stock with a buy rating and $20 price target. The analyst believes the stock is poised for growth thanks to its U.S. sales plans.
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
$BFRIBiofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
$APVOAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
$KZR Long term PT 35 and higherKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
Possibly the most undervalued stock on the TSX!- $19M mkt cap / 11M float
- $28.4M cash eq.
- $17.1M Q3 revenue / $7M adjusted EBITDA
- Options at $3.27
- Warrants at $3.53
- Enterprise value (as of Sep 30, 2021): $103.8M!!
- Canadian Commercial business is focused on Pain, Neurology, Allergy, And Dermatology therapeutics.
- 17 Global Distribution Partners across 31 Countries.
- Over 100 global patents and patent applications
- 20+ products, 7 proprietary products, ~ 100 employees
The hidden gem is Ready to explode Easy & risky trade
Price target as shown on the graph
Loss is 5%
Gain is 40% and above
Does it worth a try! Think about it and trade safe
Biotech primed for a move higher?This one is almost pure intuition. We're in pharmaceuticals earnings season now. Seagen reports after market today. A bunch of other large holdings of XBI report on November 3-4, and a bunch more on November 8. Bonds and tech stocks have made a breakout move upward, and small caps look primed. (XBI is full of small and micro caps.) XBI has had a long consolidation here, and I really like the price action on it today. A lot of other sector funds have had mid-day pullbacks, but XBI has maintained its steady upward slope. It has poked above the 20-day EMA. My guess is that this will be green again tomorrow, so I've rolled the dice on a call expiring October 29. I'm also looking for continuation the next two weeks, with a first target of about 131.75.
SPRB - 8M FLOAT - WORTH X2-X3 CURRENT PRICEAll,
I am already scaled in big here. I am without a doubt this stock will at least double.
***KEEP IN MIND THIS IS AN 8M FLOAT COMPANY
1. Do your own DD you will notice all that has really happened is low float short sellers have just railed the price down
2. This companies price targets are insane not to mention 8M float will make this EXPLODE on any good news. The company is already undervalued + postiive news of any kind just blows this baby to the moon. Except here the moon is probably where it SHOULD be.
3. Financially speaking easily in great position no chance of offerings
4. Promising company overall
5. This downtrend looks awful, but is purely short sellers and look at the length of the time on market.
This looks like it may happen soon, but either way I will happily add large position scales into this stock and simply wait. I really think at some point even a year from now we see 20+. The question is do you want to chase stocks daily, weekly or scale in. Either way set alers and volume alerts.